Dawit Ghebremedhin
Good morning, everyone. Welcome. Thank you for joining us. My name is Dawit Ghebremedhin, I’m an associate on health care team at JPMorgan. And today, I have the pleasure of introducing the Bioventus team. Joining us today is CEO, Rob Claypoole; and CFO, Mark Singleton.
Just a quick reminder on format. This will be a 20-minute presentation followed by 20 minutes of Q&A. So please save any questions until the end of the presentation.
And with that, I’ll pass it off to Rob. Thank you.
Robert Claypoole
President, CEO & Director
All right. Thanks for the introduction, Dawit, and good morning, everyone. Appreciate you joining us today. At Bioventus, our mission is to help patients recover and live life to the fullest.
I’m entering my third year as CEO and over the next few minutes, I’d like to do 2 things. First, highlight the significant changes and the strong performance that we’ve driven over the past few years. And second, show you that Bioventus is now at a very exciting inflection point, where we’re focused on igniting 4 powerful growth drivers while continuing to expand profitability increase cash flow and drive shareholder value.
But before we dive into it, a slide that you’re all familiar with. My remarks today will include some forward-looking statements and also reference non-GAAP metrics. The forward-looking statements may differ from actual results and involve the risks that are outlined in our recent filings with the SEC, which are also available on our website.
Okay. With that behind us, let me provide you with a brief summary of
